Research Radartracking 85 published studies · 25 human · 14 clinical trials · 16 cancer pages · updated Jun 2026Open the Research Map →

Prostate Cancer

Auto-discovered from research; not yet curated.

Auto-added · review pending
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceInsufficient evidenceMixed results⚠ Studies disagree
2 published studies that name Prostate Cancer0 human studies approved & graded (trial, observational, or meta-analysis)161 human clinical studies in the Prostate Cancer corpus854 source documents in the Prostate Cancer corpus
Why this grade?

Insufficient evidence — No primary experimental studies yet.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • Fuzuloparib

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Prostate Cancer.

Treatment map: Prostate Cancer

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

1
Interventions
0
Standard of care
0
Tested in people
1
Lab / animal
0
Named in lit.
1
Classes
Standard of care (0) Guideline option (0) Tested in people (0) Lab / animal only (1) Named in the literature (0)
Investigational & adjunct compounds — detail (1)
Lab / animal only
Fuzuloparib

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Get cited updates on Prostate Cancer
A monthly email when the research changes — $10/mo. Manage follows
Follow Prostate Cancer

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
87
Meta-analysis
113
Systematic review
30
Randomized trial
2
Clinical trial
6
Observational
0
Case report
13
Review
603
Preclinical
0
Other
0

Living document — last change June 9, 2026: New cancer type added.

Overview

Prostate Cancer is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.

Medicines & supplements studied for Prostate Cancer

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Prostate Cancer, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 1

FuzuloparibInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Fuzuloparib: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.
Other1 studyFull profile →

What recent studies report in Prostate Cancer

These are reviewed studies whose abstracts concern Prostate Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Prostate Cancer. Most are early lab, animal, or small human studies, and findings often conflict.

2 studies⚠ Conflicting evidenceMechanism (1)Trial (1)

Tracking 2 published studies of Prostate Cancer: 2 reviews/other.

Reported direction across studies: 1 positive, 1 mixed.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is absent so far.

These counts summarize what the studies reported; they are not a measure of whether anything works for Prostate Cancer.

Compounds with studies mentioning Prostate Cancer

Fuzuloparib (1)
ReviewMechanismMixed resultsLimited evidenceTier 1 · lab

Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule?

International journal of molecular sciences · Aug 2021 · review

breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma

This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.

Key findings
  • High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
  • Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
  • The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
  • The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.
Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..

This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewTrialReported positiveModerate evidenceTier 4 · clinical

Fuzuloparib: First Approval

Drugs · Jul 2021 · review article summarizing drug development and approval

Fuzuloparibovarian cancerfallopian tube cancerprimary peritoneal cancersolid cancerspancreatic cancerbreast cancerprostate cancerlung cancer

This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.

Key findings
  • Fuzuloparib is an orally active PARP inhibitor.
  • It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
  • Phase II and III trials are investigating it in other solid cancers.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..

This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Prostate Cancer →

Compounds with reported-positive results in Prostate Cancer

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (1)
Fuzuloparib1 positive
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
Cited positive studies (1)

Evidence at a glance: compounds studied in Prostate Cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

FuzuloparibInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Fuzuloparib: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.

Clinical trials in Prostate Cancer

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Prostate Cancer — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →